See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus
"Horisont 2020 programm" projekt MARBS15036R
MARBS15036R "Siirdegenoomika ja personaalmeditsiini õppetool (1.07.2015−31.12.2020)", Alireza Fazeli, Tartu Ülikool, Arstiteaduskond, Bio- ja siirdemeditsiini instituut, Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut.
MARBS15036R
Siirdegenoomika ja personaalmeditsiini õppetool
The ERA Chair for Translational Genomics and Personalized Medicine
TransGeno
1.07.2015
31.12.2020
Teadus- ja arendusprojekt
Horisont 2020 programm
ETIS klassifikaatorAlamvaldkondCERCS klassifikaatorFrascati Manual’i klassifikaatorProtsent
3. Terviseuuringud3.1. BiomeditsiinB470 Füsioloogia 3.1. Biomeditsiin (anatoomia, tsütoloogia, füsioloogia, geneetika, farmaatsia, farmakoloogia, kliiniline keemia, kliiniline mikrobioloogia, patoloogia)50,0
3. Terviseuuringud3.7. Kliiniline meditsiinB520 Üldpatoloogia, patoloogiline anatoomia 3.2. Kliiniline meditsiin (anestesioloogia, pediaatria, sünnitusabi ja günekoloogia, sisehaigused, kirurgia, stomatoloogia, neuroloogia, psühhiaatria, radioloogia, terapeutika, otorinolarüngoloogia, oftalmoloogia)50,0
AsutusRiikTüüp
Euroopa Komisjon
PerioodSumma
01.07.2015−31.12.20202 409 700,00 EUR
2 409 700,00 EUR

Siirdegenoomika ja personaalmeditsiini õppetool
TransGeno seeks to hire a top researcher as ERA Chair of Translational Genomics at the University of Tartu (UT). In addition to assembling a highly skilled team to engage in cutting edge translational genomic research, the ERA Chair will promote change throughout the university in several ways: • Establishing the Centre of Translational Genomics as a permanent and sustainable unit within UT • Implementing a PhD curriculum on Translational Genomics - the first one of its kind in Eastern Europe. • Coordinate with other departments to make more efficient and effective use of UT’s research capacity. • Forge partnerships with leading institutions to attract top students and researchers from around the world as well as additional funding. TG applies innovations from genomics to diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. It enables scientists to understand the genetic components of disease, which could lead to a shift from treatment based on symptoms to treatment based on underlying causes of disease. As Europe’s population ages and people must live with chronic diseases for longer this becomes more important. Advances in TG research could lead to early treatment of diseases and in the most ideal scenarios, enable doctors to treat patients before the onset of disease. TransGeno will increase research excellence in Estonia and enable UT to become a world leader in these efforts.
KirjeldusProtsent
Alusuuring100,0